20-F: Hong Kong Pharma Reports Net Loss Amid Rising Costs

Hong Kong Pharma Digital Technology Holdings Limited reported a net loss for the fiscal year ended March 31, 2025, despite an increase in total revenue, primarily due to a disproportionate rise in cost of revenues and increased operating expenses.

Summary

• Total revenue for the fiscal year ended March 31, 2025, increased by 22% to $20,313,818 from $16,688,364 in the prior year.
• Revenue from Supply Chain Services grew by 23% to $12,481,187, while Procurement and Distribution revenue increased by 21% to $7,511,591.
• Cost of revenues surged by 36% to $17,898,659, outpacing revenue growth and leading to a decrease in gross profit margin from 21% to 12%.
• The company recorded a net loss of $27,056 for the fiscal year ended March 31, 2025, a significant decline from a net profit of $1,329,717 in the previous year.
• Selling, general, and administrative expenses increased by 17% to $2,215,859, mainly due to higher professional service expenses as a Nasdaq-listed company.
• Cash and cash equivalents stood at $748,721 as of March 31, 2025.
• The company completed its initial public offering (IPO) on January 16, 2025, raising gross proceeds of $4,000,000 for the company.
• A 1-for-10 forward stock split was effected on October 24, 2024, increasing outstanding shares from 1,000,000 to 10,000,000.
• The company invested $2,299,975 into an open-end private equity fund, Evergreen Equity Fund, in February 2025, resulting in a revaluation loss of $43,145.
• The company's CEO and Chairman, Mr. Lap Sun Wong, holds approximately 56.77% of the voting power of outstanding share capital.

Sentiment

Score: 3

Explanation: The company experienced a significant decline from net profit to net loss, driven by disproportionately higher cost of revenues and increased operating expenses. While revenue growth is positive, the sharp drop in profitability and identified material weaknesses in internal controls, coupled with ongoing geopolitical and delisting risks, indicate a challenging financial position and outlook. The IPO proceeds and strategic plans offer some future potential, but current performance is concerning.

Positives

• Total revenue increased by 22% year-over-year, driven by growth in both Supply Chain Services (23%) and Procurement and Distribution (21%).
• The Supply Chain Services were more accepted by the market, leading to an increase in customer base.
• The company successfully completed its IPO on January 16, 2025, raising $4,000,000 in gross proceeds for the company.
• The company's facilities have been designated as the CaiNiao Pharmaceutical Logistics Centre in Hong Kong, indicating strong performance and a solid foundation for long-term cooperation.
• The company has established strategic cooperation agreements with major e-commerce platforms or their affiliated logistics partners in China, including Tmall, JD.com, and Meituan.
• The company possesses advanced proprietary technology infrastructure, including the 'Extraordinary Supply Chain V2.0' ERP system, which enhances operational efficiency and scalability.
• The company has obtained all necessary licenses and permits for its operations, demonstrating strong regulatory compliance.
• The management team is seasoned and visionary, with extensive experience in logistics, cross-border e-commerce, and the pharmaceutical industry.

Negatives

• The company reported a net loss of $27,056 for the fiscal year ended March 31, 2025, a significant decrease from a net profit of $1,329,717 in the prior year.
• Gross profit decreased by 32% due to a 36% increase in cost of revenues, which outpaced the 22% revenue growth, leading to a reduced gross profit margin from 21% to 12%.
• Selling, general, and administrative expenses increased by 17%, primarily due to higher professional service expenses associated with being a Nasdaq-listed company.
• The company incurred a revaluation loss of $43,145 on its investment in Evergreen Equity Fund.
• The company's share price has dipped under $1 in the past, increasing the risk of delisting from Nasdaq due to failure to maintain the minimum bid price requirement.
• The company has identified material weaknesses in its internal control over financial reporting, including a lack of sufficient financial reporting personnel with IFRS and SEC reporting knowledge, lack of formal accounting policies, and improper approval procedures for related party transactions.
• The company's dependence on a few major customers remains a risk, with CaiNiao accounting for 11.54% of total revenues in fiscal year 2025.

Risks

• Intense competition in the broader supply chain services industry, especially if large logistics service providers expand into OTC pharmaceutical supply chain services.
• Highly competitive and evolving markets for OTC pharmaceutical cross-border procurement and distribution, potentially leading to price compression.
• Loss of significant customers could materially and adversely impact financial performance and business prospects.
• Failure to cost-efficiently attract new customers or maintain relationships with existing ones could adversely affect business and results of operations.
• Business and growth are significantly affected by the development of international commerce and the e-commerce industry, as well as macroeconomic factors.
• Current and future trade restrictions could materially and adversely affect business, financial condition, and results of operations.
• Risks associated with OTC pharmaceutical inventories handled through logistics networks, including quality/health issues, personal injury, product damage, and transportation-related incidents.
• Failure to successfully implement business strategy, effectively respond to market dynamics, and meet customer demands may cause future financial results to suffer.
• Any disruption to warehousing and logistics facilities, or to the development of new facilities, could have a material adverse effect.
• Loss of suppliers or their failure to deliver products/services according to schedules, prices, quality, and volumes could impact operations.
• Inadequate insurance coverage could expose the company to significant costs and business disruptions.
• Failure to comply with applicable complex laws and regulations could lead to significant adverse regulatory actions or reputational harm.
• Failure to obtain certain filings, approvals, licenses, permits, and certificates required for business operations may materially and adversely affect the company.
• The failure or disruption of information technology systems or infrastructure could adversely affect reputation, business, operating results, and cash flows.
• Data governance failures can adversely affect reputation, businesses, and prospects, especially regarding sensitive customer information.
• Business depends on the continued efforts of senior management; loss of key executives could severely disrupt the business.
• Failure of business divisions to effectively synchronize could prevent maximization of operating results.
• Negative public perception of the OTC pharmaceutical industry can adversely affect business, operating results, cash flows, and prospects.
• Acquisitions, joint ventures, strategic alliances, and divestitures may be unsuccessful, cause unanticipated liabilities, or disrupt existing businesses.
• Reliance on dividends and distributions from HK Subsidiaries, with potential limitations on transfers by the PRC government.
• Failure to achieve and maintain effective internal controls could adversely affect business and securities price.
• Exposure to foreign currency risk, particularly between USD and HKD.
• Legal and operational risks associated with operations in China may apply to Hong Kong operations, with potential for significant oversight and control by the Chinese government.
• Enactment of the Hong Kong National Security Law could impact Hong Kong operating subsidiaries.
• Changes in Hong Kong's economic, political, or social conditions or government policies could have a material adverse effect.
• Political risks associated with conducting business in Hong Kong, including social unrest or natural disasters.
• Additional and more stringent criteria applied to U.S.-listed companies with significant operations in China and Hong Kong could add uncertainties.
• Evolving Hong Kong and China legal systems embody uncertainties, limiting legal protections.
• Potential subjection to PRC laws and obligations regarding cybersecurity, data protection, overseas offerings, and foreign investment.
• Risk of delisting from Nasdaq due to failure to maintain minimum bid price requirement (share price dipped under $1 in April and May 2025).
• Market price of Ordinary Shares has been volatile or may decline regardless of operating performance.
• Inability to maintain Nasdaq listing.
• Unfavorable research or cessation of coverage by securities/industry analysts could cause share price/trading volume decline.
• No historical dividends, so return on investment depends on share price appreciation.
• Issuance of additional equity or debt securities could adversely affect market price and dilute existing shareholders.
• CEO and Chairman, Mr. Lap Sun Wong, holds majority voting power, limiting other shareholders' influence.
• Subject to less rigorous ongoing public reporting requirements as an emerging growth company.
• Exempt from certain provisions applicable to U.S. domestic public companies as a foreign private issuer.
• Permitted to rely on exemptions from certain Nasdaq corporate governance standards as a foreign private issuer.
• Loss of foreign private issuer status in the future could result in significant additional costs.
• Shareholders may be unable to present proposals before annual or extraordinary general meetings not called by shareholders.
• Certain judgments obtained against the company and selling shareholders by Hong Kong Pharma's shareholders may not be enforceable.
• Difficulties in protecting interests and limited ability to protect rights through U.S. courts due to Cayman Islands incorporation.
• Memorandum and articles of association contain anti-takeover provisions.
• Cayman Islands economic substance requirements may affect business and operations.
• Risk of being a passive foreign investment company (PFIC) for any taxable year, resulting in adverse U.S. federal income tax consequences.
• Adverse developments in general business and economic conditions, as well as global capital market conditions, could affect demand.
• Inclement weather, widespread illness outbreaks, anti-terrorism measures, and other disruptions could negatively affect supply chain and operations.
• Exposure to claims, controversies, lawsuits, and legal proceedings.
• Geopolitical instability (Russia-Ukraine, Israel-Hamas conflicts) could materially and adversely affect business, financial condition, and results of operations.

Future Outlook

The company plans to continuously upgrade its technology infrastructure by implementing smart shipping/receiving equipment and automating assembly lines to reduce labor costs and improve warehouse utilization. It also intends to develop a comprehensive cross-border OTC pharmaceutical service platform. The company aims to expand its sales team, particularly in Mainland China, to acquire more merchants and diversify its customer base. Furthermore, it plans to optimize working capital management by improving accounts receivable turnover, establishing robust credit management, and reducing inventory turnover times to enhance cash flow and capital utilization efficiency. The company is also focusing on developing internet hospitals in Mainland China as a new revenue source.

Management Comments

• We believe our advanced technological capabilities, vast experience in the OTC pharmaceutical supply chain service industry, and e-commerce insights can further entrench our position as an ever more important player in Mainland China's OTC pharmaceutical cross-border e-commerce market.
• We believe our reliable performance and years of track record in serving CaiNiao have laid a solid foundation for long-term cooperation with CaiNiao, and this stands as a hallmark of our quality services, serving as a cornerstone for our growth in the high-growth OTC pharmaceutical cross-border e-commerce supply chain market in Mainland China.
• We expect to maintain our business relationships with our existing major customers, and simultaneously strive to diversify our pool of customers as we develop our business to reduce the risk of our dependence on a few major customers.
• We believe the efficiency of our technology infrastructure is a critical factor in determining our market competitiveness.
• We believe that overall improvement in processing and equipment, combined with further optimization of the operational system, will further distinguish us from our competitors.
• We believe that our current levels of cash and cash flows from operations will be sufficient to meet our anticipated cash needs for our operations and expansion plans for at least the next 12 months.

Industry Context

The company operates in the highly competitive and evolving OTC pharmaceutical cross-border e-commerce supply chain industry, primarily serving the Mainland China market from Hong Kong. It leverages the significant and growing demand for overseas OTC pharmaceuticals by Chinese consumers, facilitated by online platforms. The industry is sensitive to macroeconomic conditions, e-commerce growth, and regulatory changes. The company positions itself as a one-stop solution provider, differentiating through technology, scale, flexibility, and regulatory compliance. The trend of online and offline retail channel integration and the rise of internet hospitals are key industry developments impacting the company's strategy.

Comparison to Industry Standards

• The company ranked first in Mainland China's OTC pharmaceutical cross-border e-commerce supply chain service market by revenue in 2022, according to the F&S Report, indicating a leading market position.
• The company's facilities have been designated as the CaiNiao Pharmaceutical Logistics Centre in Hong Kong, a testament to its stable and stellar fulfillment performance, suggesting a high standard of service comparable to major logistics partners.
• The company's proprietary ERP software system, 'Extraordinary Supply Chain V2.0,' aims to reduce logistics fulfillment costs and increase efficiency, which is a competitive advantage in a fragmented and competitive logistics industry.
• The company's ability to secure and collaborate with major platform logistics partners like CaiNiao and top-tier merchants allows it to capitalize on economies of scale, potentially offering more competitive prices and services compared to smaller, less integrated competitors.
• The company's comprehensive regulatory compliance, including all necessary licenses and permits for OTC pharmaceutical import/export and storage, positions it favorably against competitors navigating complex international regulations.

Management Changes

Corporate Governance

Legal Proceedings

• The company is currently not aware of any legal proceedings or claims that are believed to have a material adverse effect on its business, financial condition, or operating results.

Related Party Transactions

• The company has engaged in transactions with its directors, officers, and principal shareholders, including Mr. Lap Sun Wong, Mr. Zhifang Zhang, Wing Hong Pharmaceutical Limited, HongKong Profit Fields Group Limited, Hangzhou Liku Electronic Commercial Co., Ltd., My Brand Management Limited, Billion Built International Limited, and Fame Overseas Supply Chain Limited.
• Related party receivables/payables were unsecured, non-interest bearing, and repayable on demand.
• For the year ended March 31, 2025, Mr. Lap Sun Wong received $248,023 in loans from related parties, and Mr. Zhifang Zhang received $571,152 in loans from related parties.
• For the year ended March 31, 2024, Mr. Lap Sun Wong received $243,427 in loans from related parties, and Mr. Zhifang Zhang received $124,889 in loans from related parties.
• The company believes the terms of these transactions were comparable to arms-length transactions, but acknowledges potential for conflicts of interest.

Stakeholder Impact

• **Shareholders**: Experience a net loss for the fiscal year, potentially impacting share price and investment return. Dilution risk from future equity issuances. Risk of delisting from Nasdaq due to bid price issues. Limited influence on corporate matters due to majority voting power held by CEO.
• **Employees**: The company maintains employee compensation and medical insurance. Average number of outsourced workers decreased slightly from 80 to 76 per day. Overall employee relations are considered good.
• **Customers**: Continued focus on providing cost-effective products and quality logistics services. Expansion of sales team and technology upgrades aim to improve customer experience and acquisition. Dependence on a few major customers (e.g., CaiNiao) poses a risk if relationships deteriorate.
• **Suppliers**: The company relies on various suppliers (pharmaceutical producers/distributors, logistics subcontractors, labor, packaging). Loss of key suppliers or their failure to deliver could disrupt operations. One supplier accounted for 13.72% of total purchases in fiscal year 2025.
• **Creditors**: The company has incurred increased indebtedness, which could affect its financial condition and ability to service debt if cash flow from operations is insufficient.

Next Steps

• Continuously upgrade technology infrastructure, including implementing smart shipping/receiving equipment and automating assembly lines.
• Develop a comprehensive cross-border OTC pharmaceutical service platform.
• Expand the sales team in Mainland China to acquire more merchants and diversify the customer base.
• Optimize working capital management to improve accounts receivable turnover rates, establish robust credit management, and reduce inventory turnover times.
• Pursue opportunities to drive sales growth and expand sales channels, including developing internet hospitals as a new source of revenue.
• Implement measures to address identified material weaknesses in internal control over financial reporting, including hiring qualified staff, formalizing policies, and improving approval procedures for related party transactions.
• Review and renew existing insurance coverage before expiration to ensure adequacy.

Key Dates

Recommendation

Hong Kong Pharma's recent financial performance, marked by a shift from profit to a net loss and a significant decline in gross profit margin, raises concerns about its operational efficiency and cost management. While revenue growth is positive and the company has a strong market position in a niche industry, the substantial increase in cost of revenues and administrative expenses, coupled with identified internal control weaknesses, indicates underlying issues. The risk of Nasdaq delisting due to bid price volatility and geopolitical uncertainties in Hong Kong further adds to the investment risk. However, the company's strategic plans for technology upgrades, sales expansion, and working capital optimization, along with its recent IPO proceeds, offer potential for future improvement. Given the mixed signals – growth in revenue but a decline in profitability, significant risks but also clear strategic initiatives – a 'hold' recommendation is appropriate. Investors should monitor the company's progress in addressing its internal control issues, improving profitability, and navigating the complex regulatory and market environment before considering further investment.

Keywords

OTC pharmaceutical, cross-border e-commerce, supply chain services, logistics, Hong Kong, China, pharmaceutical distribution, e-commerce platforms, Nasdaq, SEC filing, Form 20-F, financial results, risk factors, corporate governance, international trade, healthcare logistics